173P Extended-stage SCLC (ES-SCLC) patients treated with first-line chemotherapy plus atezolizumab in Spain: Characteristics and outcomes

Autor: Gómez-Mugarza, P., Laguna, S., Zapata, M., Prado, L. Fernandez, Gimeno, J., Nuño, A., Galan, N., Arnaiz, I. Gil, Artal-Cortes, A.

Publikováno v: In Journal of Thoracic Oncology April 2023 18(4) Supplement:S135-S136

P-69 Anal squamous cell carcinoma (ASCC) outcomes in clinical practice: From localized to metastatic setting

Autor: Esteban Villarrubia, J., Hernando, J., Gómez Mugarza, P., García Álvarez, A., Torres Jiménez, J., Orejana Martín, I., Alonso Orduña, V., Gómez-Puerto, D., Álvarez Ballesteros, P., Polo, E., López, D., Martínez Delfrade, Í., López Roldán, B., Roca, M., Reguera Puertas, P., Barriendos Sanz, S., Benini, L., Ferreiro Monteagudo, R., Monreal Cepero, M., Campos Ramírez, S., Guillén-Ponce, C., Capdevila, J.

Publikováno v: In Annals of Oncology June 2022 33 Supplement 4:S272-S272

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sequential therapy with induction chemotherapy and chemoradiotherapy in pre-irradiated recurrent head and neck squamous cell carcinoma incorporating nab-paclitaxel-a commentary of the phase I trial of AFHX followed by concomitant FHX scheme.

Autor: Martinez-Trufero J; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Comin Orce A; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Gomez Mugarza P; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Barriendos Sanz S; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Ortega Izquierdo E; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain.

Publikováno v: Translational cancer research [Transl Cancer Res] 2023 Apr 28; Vol. 12 (4), pp. 692-696. Date of Electronic Publication: 2023 Apr 06.